1. Home
  2. WKC vs MLYS Comparison

WKC vs MLYS Comparison

Compare WKC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo World Kinect Corporation

WKC

World Kinect Corporation

N/A

Current Price

$37.29

Market Cap

1.8B

Sector

Energy

ML Signal

N/A

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$15.84

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WKC
MLYS
Founded
1984
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.9B
IPO Year
1994
2023

Fundamental Metrics

Financial Performance
Metric
WKC
MLYS
Price
$37.29
$15.84
Analyst Decision
Sell
Strong Buy
Analyst Count
3
11
Target Price
$37.00
★ $45.22
AVG Volume (30 Days)
709.9K
★ 1.5M
Earning Date
10-29-2026
11-04-2026
Dividend Yield
★ 2.46%
N/A
EPS Growth
N/A
★ 37.43
EPS
★ 2.14
N/A
Revenue
★ $36,916,600,000.00
N/A
Revenue This Year
$35.40
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$25.98
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$22.21
$18.12
52 Week High
$41.20
$47.65

Technical Indicators

Market Signals
Indicator
WKC
MLYS
Relative Strength Index (RSI) 61.25 24.38
Support Level $34.97 N/A
Resistance Level $37.88 $31.19
Average True Range (ATR) 0.96 1.35
MACD 0.10 -0.23
Stochastic Oscillator 80.07 4.23

Price Performance

Historical Comparison
WKC
MLYS

About WKC World Kinect Corporation

World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. It earns the majority of its revenue from the Aviation segment.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: